Nivolumab

Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer

Retrieved on: 
Monday, October 9, 2023

THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Tom Garner is joining the company as senior vice president and chief commercial officer, effective October 9, 2023.

Key Points: 
  • THE WOODLANDS, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Tom Garner is joining the company as senior vice president and chief commercial officer, effective October 9, 2023.
  • During his time at BMS, Mr. Garner held a broad array of roles throughout BMS’ commercial organization including positions at local, country, and global levels, and across a diverse range of brands and therapeutic areas.
  • In his most recent role, Mr. Garner was the senior vice president and head of the U.S. Cardiovascular and Established Brands business unit, the single largest business unit across the BMS enterprise with reported total revenues in excess of $10 billion.
  • “We are very excited that Mr. Garner is joining Lexicon as our chief commercial officer,” said Lonnel Coats, Lexicon’s chief executive officer.

Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action

Retrieved on: 
Friday, October 6, 2023

The poster shows that higher pre-treatment levels of tumor infiltrating lymphocytes that express CEACAM1may associated with longer survival in patients treated with CM24 and nivolumab.

Key Points: 
  • The poster shows that higher pre-treatment levels of tumor infiltrating lymphocytes that express CEACAM1may associated with longer survival in patients treated with CM24 and nivolumab.
  • “These encouraging data, demonstrating increased survival of PDAC patients whose biopsies show higher CEACAM1-positive lymphocytes, are consistent with the CM24 Mechanism of Action (MoA) in suppressing the immune evasion and suggest CEACAM1 expressing lymphocytes as a potential biomarker for CM24 therapy” said Purple Biotech VP R&D, Dr. Hadas Reuveni.
  • “NETs and CEACAM1 will continue to be monitored and investigated in our ongoing randomized Phase 2 study of CM24 in pancreatic cancer patients,” stated Purple Biotech CEO, Gil Efron.
  • “We look forward to reporting data from this study in the near term.”

IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board

Retrieved on: 
Friday, October 6, 2023

LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company’s scientific advisory board.

Key Points: 
  • LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company’s scientific advisory board.
  • Dr. Ott is the Clinical Director of the Melanoma Disease Center and the Director, Clinical Sciences, of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute.
  • He joins current scientific advisory board members Dan H. Barouch, M.D., Ph.D., Luke D. Handke, Ph.D., Sachet A. Shukla, Ph.D. and John W. Shiver, Ph.D.
    “We are honored that Dr. Ott has agreed to our scientific advisory board and believe that he will offer invaluable guidance as we further develop our technologies and advance our pipeline,” said Dr. Corinne Le Goff, president and chief executive officer of IMUNON.
  • Dr. Ott has been Principal Investigator of a first-in-human clinical trial testing a personalized vaccine (NeoVax) in patients with melanoma.

CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation

Retrieved on: 
Sunday, October 15, 2023

CatalYm today announced new preclinical data expanding the mechanistic understanding of how GDF-15 plays a key role in cancer therapy resistance.

Key Points: 
  • CatalYm today announced new preclinical data expanding the mechanistic understanding of how GDF-15 plays a key role in cancer therapy resistance.
  • The data are the first to show that GDF-15 has an inhibitory effect on the activation of M1 macrophages.
  • These specific myeloid lineage immune cells are central to the initiation of immune responses, including the secretion of pro-inflammatory cytokines and chemokines, presentation of antigens as well as direct antitumor cytotoxicity.
  • Overall, the results indicate that GDF-15 counteracts myeloid immune cell activation, supporting the generation of an immune-evasive tumor microenvironment, an important feature in therapy resistance.

SOTIO Announces First Patients Dosed in Two Combination Arms of CLAUDIO-01 Study Evaluating SOT102 in First-Line Gastric and Pancreatic Cancer

Retrieved on: 
Wednesday, October 11, 2023

CLAUDIO-01 is evaluating SOTIO’s potent antibody-drug conjugate SOT102 in patients with gastric and pancreatic cancer.

Key Points: 
  • CLAUDIO-01 is evaluating SOTIO’s potent antibody-drug conjugate SOT102 in patients with gastric and pancreatic cancer.
  • The combination arms will be the first clinical evaluation of SOT102’s potential as a first-line cancer treatment in combination with current standard of care.
  • In the gastric cancer arm, SOT102 will be combined with mFOLFOX plus nivolumab.
  • In the trial’s combination arm, by contrast, SOT102 will be dosed in combination with standard-of-care as a first-line treatment for patients with advanced/metastatic gastric/gastroesophageal junction (GEJ) or pancreatic cancers.

Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023

Retrieved on: 
Thursday, October 12, 2023

Data from the Phase 3 CheckMate -901 and CheckMate -77T studies have been selected for presentation in Presidential Symposium sessions.

Key Points: 
  • Data from the Phase 3 CheckMate -901 and CheckMate -77T studies have been selected for presentation in Presidential Symposium sessions.
  • Data to be presented support the role of Opdivo and Opdivo-based combinations in both earlier and metastatic stages of multiple cancer types, especially in patient groups with high unmet needs.
  • , executive vice president, chief medical officer, Global Drug Development, Bristol Myers Squibb.
  • Additional CheckMate -816 results will also be presented showing efficacy benefits with Opdivo plus Yervoy in resectable NSCLC.

Melanoma Research Alliance Applauds Expanded Approval of Nivolumab to Patients with Stage 2 Disease

Retrieved on: 
Monday, October 16, 2023

While surgery is curative for most patients with early-stage disease, up to one third of patients with stage IIB and up to half of patients with IIC melanoma will have a recurrence within five years.

Key Points: 
  • While surgery is curative for most patients with early-stage disease, up to one third of patients with stage IIB and up to half of patients with IIC melanoma will have a recurrence within five years.
  • Reducing the risk of recurrence after surgery – and the progression to more advanced disease – is an important goal for clinicians and patients alike.
  • Nivolumab, an anti-PD-1 antibody, works by stimulating the patient's immune system to attack melanoma by promoting the tumor-killing effectiveness of T cells.
  • "The expanded approval of nivolumab gives patients with high risk melanoma a new option to prevent recurrence following surgery," says MRA Chief Executive Officer Marc Hurlbert, PhD.

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma1

Retrieved on: 
Saturday, October 14, 2023

Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo® (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma, expanding upon the existing adjuvant indication for Opdivo and further reinforcing the company’s legacy of providing treatment options for melanoma patients.1 The approval is based on the Phase 3 CheckMate -76K trial, which compared Opdivo (n=526) to placebo (n=264).1,2

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo® (nivolumab) was approved by the U.S. Food and Drug Administration (FDA) for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected stage IIB or IIC melanoma, expanding upon the existing adjuvant indication for Opdivo and further reinforcing the company’s legacy of providing treatment options for melanoma patients.1 The approval is based on the Phase 3 CheckMate -76K trial, which compared Opdivo (n=526) to placebo (n=264).1,2
    In the trial, Opdivo reduced the risk of recurrence, new primary melanoma, or death in patients with completely resected stage IIB or IIC melanoma by 58% compared to placebo (Hazard Ratio [HR] 0.42; 95% Confidence Interval [CI]: 0.30-0.59; P “Following surgical removal of melanoma, patients may believe they are free of disease,” said John M. Kirkwood, M.D., Distinguished Professor of Medicine at the University of Pittsburgh School of Medicine and Co-Director of the Melanoma Center at UPMC Hillman Cancer Center.
  • “However, within five years of diagnosis, one-third of patients with surgically resected stage IIB and nearly one-half of patients with surgically resected IIC melanoma see their cancer return, underscoring the need for additional treatment options that may help reduce the risk of cancer coming back.4 The significant recurrence-free survival improvement observed with nivolumab in CheckMate -76K is an important step forward for these patients.”1
    Opdivo is associated with the following Warnings & Precautions: severe and fatal immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis and hepatotoxicity, endocrinopathies, dermatologic adverse reactions, nephritis with renal dysfunction, other immune-mediated adverse reactions; infusion-related reactions; complications of allogeneic hematopoietic stem cell transplantation (HSCT); embryo-fetal toxicity; and increased mortality in patients with multiple myeloma when Opdivo is added to a thalidomide analogue and dexamethasone, which is not recommended outside of controlled clinical trials.1 Please see Important Safety Information below.
  • “Stage IIB and IIC melanoma patients may still face the threat of disease recurrence, despite the benefit of surgery, which can impact outcomes,” said Catherine Owen, senior vice president and general manager, U.S. Cardiovascular, Immunology and Oncology at Bristol Myers Squibb.4,5 “This approval builds on our existing adjuvant indication in completely resected stage III or IV disease and now provides eligible patients with completely resected stage IIB or IIC melanoma an additional treatment option which may help prevent recurrence.
  • BMS remains committed to its goal of helping improve patient outcomes in melanoma and bringing immunotherapy to more patients, including in the earlier stages of disease.”1
    The FDA previously approved Opdivo for the adjuvant treatment of adult and pediatric patients 12 years and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection, based upon data from the CheckMate -238 trial.1
    Additional CheckMate -76K follow-up data will be presented at the Society for Melanoma Research Annual Meeting in November.

Pheon Therapeutics Appoints Oncology Expert Arvin Yang, MD, PhD as Chief Medical Officer

Retrieved on: 
Tuesday, October 10, 2023

LONDON and CAMBRIDGE, Mass., Oct. 10, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, is pleased to announce the appointment of Arvin Yang, MD, PhD, as Chief Medical Officer.

Key Points: 
  • LONDON and CAMBRIDGE, Mass., Oct. 10, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, is pleased to announce the appointment of Arvin Yang, MD, PhD, as Chief Medical Officer.
  • Cyrus Mozayeni, Chief Executive Officer of Pheon Therapeutics, said: "As a seasoned Chief Medical Officer, Dr. Yang's extensive industry and leadership experience position him perfectly to take Pheon into the next stage of our growth as a clinical-stage company.
  • Dr. Arvin Yang, newly appointed Chief Medical Officer of Pheon Therapeutics, commented: "Pheon is very well positioned with its commitment to advancing its wholly owned, proprietary ADCs targeting solid tumors.
  • He has been published extensively in medical academic journals and is recognized as a leading authority in the fields of hematology and oncology.

Pheon Therapeutics Appoints Oncology Expert Arvin Yang, MD, PhD as Chief Medical Officer

Retrieved on: 
Tuesday, October 10, 2023

LONDON and CAMBRIDGE, Mass., Oct. 10, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, is pleased to announce the appointment of Arvin Yang, MD, PhD, as Chief Medical Officer.

Key Points: 
  • LONDON and CAMBRIDGE, Mass., Oct. 10, 2023 /PRNewswire/ -- Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers, is pleased to announce the appointment of Arvin Yang, MD, PhD, as Chief Medical Officer.
  • Cyrus Mozayeni, Chief Executive Officer of Pheon Therapeutics, said: "As a seasoned Chief Medical Officer, Dr. Yang's extensive industry and leadership experience position him perfectly to take Pheon into the next stage of our growth as a clinical-stage company.
  • Dr. Arvin Yang, newly appointed Chief Medical Officer of Pheon Therapeutics, commented: "Pheon is very well positioned with its commitment to advancing its wholly owned, proprietary ADCs targeting solid tumors.
  • He has been published extensively in medical academic journals and is recognized as a leading authority in the fields of hematology and oncology.